NKTR - Nektar Therapeutics
| Previous Close | 19.86 |
| Open | 20.07 |
| Bid | 20.34 x 900 |
| Ask | 20.98 x 2900 |
| Day's Range | 19.96 - 21.00 |
| 52 Week Range | 15.64 - 47.11 |
| Volume | 2190285 |
| Avg. Volume | 3,529,823 |
| Market Cap | 3.6B |
| Beta (3Y Monthly) | 2.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.44 |
| Earnings Date | Feb 26, 2020 - Mar 2, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.38 |
- Zacks
Why Is Nektar (NKTR) Up 6.2% Since Last Earnings Report?
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire
Nektar Appoints John Northcott as Chief Commercial Officer
Nektar Therapeutics (NASDAQ:NKTR) announced today that John Northcott has joined the company in the newly-created position of Senior Vice President and Chief Commercial Officer. John will also serve as a member of the Company's Executive Committee reporting directly to President and CEO, Howard W. Robin.
- PR Newswire
Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference
SAN FRANCISCO , Nov. 13, 2019 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to present at the upcoming Jefferies 2019 Healthcare Conference in London on Wednesday, ...
- Thomson Reuters StreetEvents
Edited Transcript of NKTR earnings conference call or presentation 6-Nov-19 10:00pm GMT
Q3 2019 Nektar Therapeutics Earnings Call
- Investor's Business Daily
Can This Biotech Improve On Bristol-Myers' Blockbuster Cancer Drug?
Shares of Nektar Therapeutics popped Monday after the biotech company's Bristol-Myers Squibb-partnered regimen continued to show promise in never-before-treated melanoma patients.
- Barrons.com
Nektar Therapeutics Stock Is Rising on Test Data for Cancer Drug
The company released clinical data that raised hope about a drug-development program that has encountered manufacturing problems.
- PR Newswire
Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
SAN FRANCISCO, Nov. 10, 2019 /PRNewswire/ -- Nektar Therapeutics (NKTR) today announced updated results from the first-in-human Phase 1a study of NKTR-358, a novel T regulatory (Treg) cell stimulator in development for the treatment of autoimmune and other chronic inflammatory conditions. The data, which were presented at the 2019 Annual Meeting of the American College of Rheumatology in Atlanta, show that treatment with NKTR-358 led to a marked and selective dose-dependent expansion in the numbers and proliferative capacity of FoxP3+CD25bright Treg cells, and a measurable activation of Treg cells. NKTR-358 is designed to treat autoimmune and inflammatory conditions by correcting the immune system imbalance that results from reduced numbers and impaired function of immune-regulating Treg cells.
- PR Newswire
Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
New Data Presented for Previously Untreated Metastatic Melanoma Patients in PIVOT-02 Study of Bempegaldesleukin with Nivolumab Additional Preclinical Data Presentations Showcase Nektar's Immuno-Oncology ...
- Zacks
Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up
Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.
- Zacks
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 23.29% and 11.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019
SAN FRANCISCO , Nov. 6, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2019 . Cash and investments in marketable ...
- Benzinga
The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight
Biotech stocks extended their gains last week amid earnings news flow and the broader market strength. Large-cap pharma stocks saw particular strength. Here are the key catalytic event a biotech investor ...
- PR Newswire
Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting
SAN FRANCISCO , Nov. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with a melanoma specialist and company management ...
- PR Newswire
Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , Oct. 30, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 6, 2019 , after the close of U.S.-based ...
- Zacks
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Is Nektar Therapeutics (NKTR) Going To Burn These Hedge Funds ?
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
- MoneyShow
With Good Trial Results, Nektar Therapeutics Could "Turn on a Dime"
Nektar Therapeutics (NKTR) is conducting a trial that will test NKTR-255 in patients with relapsed-refractory non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), explains biotech specialist John McCamant, editor of The Medical Technology Stock Letter.
- Benzinga
16 Stocks With The Highest Long-Term Sales Growth Rate
Longtime investors know the stock market is forward-looking. That means a stock’s share price is more a reflection of what investors collectively think the company will do in the future than what it did ...
- GlobeNewswire
DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar” or the “Company”) (NKTR) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Nektar securities between February 15, 2019 through August 8, 2019, both dates inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
- ACCESSWIRE
FINAL DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019
NEW YORK, NY / ACCESSWIRE / October 18, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the Company") ...
- ACCESSWIRE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
NEW YORK, NY / ACCESSWIRE / October 17, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR). Such investors ...
- GlobeNewswire
KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for NEKTAR THERAPEUTICS Investors – NKTR
Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (NKTR) (“Nektar”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of those who purchased or otherwise acquired Nektar securities between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”). According to the complaint, Nektar is a biopharmaceutical company that develops medicines in areas of high unmet medical need, including therapies for cancer, autoimmune disease, and chronic pain. In the PIVOT-02 clinical study, Nektar evaluates the benefit, safety, and tolerability of combining NKTR-214 with Opdivo, an antibody, in collaboration with Bristol-Meyers Squibb Company.
- Business Wire
FINAL DEADLINE APPROACHING: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (NKTR) (“Nektar”) investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or otherwise acquired Nektar securities between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”). REMINDER: Investors who purchased Nektar securities during the Class Period may, no later than October 18, 2019, seek to be appointed as a lead plaintiff representative of the class. According to the complaint, Nektar is a biopharmaceutical company that develops medicines in areas of high unmet medical need, including therapies for cancer, autoimmune disease, and chronic pain.
- Business Wire
NKTR CLASS ACTION DEADLINE IN 1 DAY: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Nektar Therapeutics
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a motion for appointment as lead plaintiff in a securities class action on behalf of investors that purchased or acquired the securities of Nektar Therapeutics ("Nektar" or the "Company") (NKTR) between February 15, 2019 and August 8, 2019, inclusive (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934. If you purchased Nektar securities, and/or would like to discuss your legal rights and options please visit Nektar Shareholder Class Action or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.
